Misoprostol: A Pharma Marvel
Authors/Creators
- 1. Assistant Professor, School of Medical Science and Research & Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh, India
Description
Misoprostol is a synthetic prostaglandin E1 analogue which was first developed in the U.S. in 1973 initially used for prevention and treatment of gastric ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs). But it had known major side effects on a pregnant uterus which induced this magic drug in the world of obstetrics and gynecology. It is used off-label for a variety of indications in the practice of obstetrics and gynecology, including medical abortion, medical management of early pregnancy failure, including an-embryonic pregnancies and embryonic demise, incomplete abortion, induction of labor, cervical ripening before surgical procedures, and the treatment of postpartum hemorrhage. Due to its wide-ranging applications in reproductive health, misoprostol is on the World Health Organization Model List of Essential Medicines. This article briefly reviews the varied routes, dosing and uses of misoprostol in obstetrics and gynecology.
Files
(11-13)Misoprostol- A Pharma Marvel-format.pdf
Files
(248.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4a199322a769bb562345e4056dde5576
|
248.3 kB | Preview Download |
Additional details
References
- Gibson, Liza. (2005). WHO puts abortifacients on its essential drug list. BMJ (Clinical research ed.). 331. 68. 10.1136/bmj.331.7508.68-c.
- Andrew D Weeks, Christian Fiala, Peter Safar (March 2005), "Misoprostol and the debate over off label drug use", BJOG, Volume 112, Issue 3, pp. 269-272.
- Fjerstad M1, Sivin I, Lichtenberg ES, Trussell J, Cleland K, Cullins V (Sep 2009), "Contraception", Volume 80, Issue 3, pp. 282−286. DOI: 10.1016/j.contraception.2009.03.010. Epub 2009 May 2.
- World Health Organization (2012), "Safe Abortion: Technical and Policy Guidance for Health Systems", Second Edition. Geneva: WHO, Available from http://apps.who.int/iris/bitstream/10665/70914/1/9789241548434_eng.pdf?ua=1.
- Misoprostol-only recommended regimens 2017,International federation of Gynecology and Obstetrics, www,figo.org
- World Health Organization. (2014). Clinical practice handbook for safe abortion. World Health Organization.
- OS Tanga, K Gemzell-Danielssonb, PC Hoa (2007), "Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects", International Journal of Gynecology and Obstetrics, Volume 99, pp. S160–S167.
- Khan RU, El-Refaey H, Sharma S et al. (2004), "Oral, rectal, and vaginal pharmacokinetics of misoprostol", Obstet Gynecol, Volume 103, pp. 866–870.
- Goldberg AB, Greenberg MB, Darney PD (2001), "Misoprostol and pregnancy", N Engl J Med., Volume 344, pp. 38–47.